Barclays PLC Acadia Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$17.79 - $30.86 $775,644 - $1.35 Million	43,600 Added 76.49%	100,600 $1.86 Million
Q4 2023 Feb 15, 2024	BUY	$20.78 - $31.77 $1.18 Million - $1.81 Million	57,000 New	57,000 $1.79 Million
Q4 2022 Feb 13, 2023	BUY	$14.2 - $18.63 $718,520 - $942,678	50,600 New	50,600 $806,000
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $10,074 - $16,254	600 Added 31.58%	2,500 $58,000
Q2 2020 Aug 12, 2020	SELL	$39.26 - $52.73 $2.61 Million - $3.51 Million	-66,500 Reduced 97.22%	1,900 $92,000
Q1 2020 May 13, 2020	SELL	$31.65 - $46.87 $9.59 Million - $14.2 Million	-303,100 Reduced 81.59%	68,400 $2.89 Million
Q4 2019 Feb 10, 2020	BUY	$36.21 - $51.4 $564,876 - $801,840	15,600 Added 4.38%	371,500 $15.9 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $2.94 Million - $5.83 Million	132,500 Added 59.31%	355,900 $12.8 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $3.79 Million - $4.57 Million	162,500 Added 266.83%	223,400 $5.97 Million
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $588,588 - $996,632	-36,400 Reduced 37.41%	60,900 $1.64 Million
Q4 2018 Feb 14, 2019	BUY	$14.32 - $22.92 $107,400 - $171,900	7,500 Added 8.35%	97,300 $1.57 Million
Q3 2018 Nov 14, 2018	BUY	$13.03 - $21.81 $203,268 - $340,236	15,600 Added 21.02%	89,800 $1.87 Million
Q2 2018 Aug 14, 2018	SELL	$15.07 - $22.34 $316,470 - $469,140	-21,000 Reduced 22.06%	74,200 $1.13 Million
Q1 2018 May 15, 2018	SELL	$22.47 - $32.33 $179,760 - $258,640	-8,000 Reduced 7.75%	95,200 $2.14 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $625,372 - $911,962	-23,300 Reduced 18.42%	103,200 $3.11 Million
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $3.73 Million - $4.85 Million	126,500	126,500 $4.77 Million

Others Institutions Holding ACAD

# of Institutions

279

Shares Held

156M

Call Options Held

901K

Put Options Held

314K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account